Citadel Advisors
CRDL

Citadel Advisors’s Cardiol Therapeutics CRDL Stock Holding History

Citadel Advisors’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103K Sell
76,600
-12,200
-14% -$12.5K ﹤0.01% 11992
2025
Q4 		$84.7K Buy
+88,800
New +$93K ﹤0.01% 11755
2025
Q3 		– Sell
-37,600
Closed -$51.1K – 12926
2025
Q2 		$51.1K Buy
37,600
+11,700
+45% +$13.6K ﹤0.01% 11756
2025
Q1 		$25.1K Buy
25,900
+21,000
+429% +$25.8K ﹤0.01% 12970
2024
Q4 		$6.27K Sell
4,900
-300
-6% -$506 ﹤0.01% 13806
2024
Q3 		$10.3K Sell
5,200
-24,200
-82% -$50.2K ﹤0.01% 13210
2024
Q2 		$59.4K Sell
29,400
-4,300
-13% -$9.12K ﹤0.01% 11572
2024
Q1 		$61K Buy
33,700
+22,900
+212% +$30.9K ﹤0.01% 11975
2023
Q4 		$9.07K Buy
+10,800
New +$9.18K ﹤0.01% 13175
2023
Q2 		– Sell
-4,500
Closed -$2.19K – 14449
2023
Q1 		$2.19K Sell
4,500
-23,900
-84% -$14.1K ﹤0.01% 14187
2022
Q4 		$14.5K Sell
28,400
-49,800
-64% -$30.4K ﹤0.01% 13392
2022
Q3 		$81K Buy
78,200
+48,700
+165% +$59.4K ﹤0.01% 11270
2022
Q2 		$39K Buy
29,500
+4,200
+17% +$5.98K ﹤0.01% 12074
2022
Q1 		$39K Sell
25,300
-51,500
-67% -$84.9K ﹤0.01% 12948
2021
Q4 		$142K Buy
+76,800
New +$212K ﹤0.01% 12333

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors's CRDL Position: Q1 2026 in Review

Citadel Advisors opened a new position in Cardiol Therapeutics (CRDL) in Q1 2026: 819,904 shares worth $1.11M. The stake represents ﹤0.01% of the portfolio and ranks #7440 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CRDL as recently as Q3 2025.

Citadel Advisors first reported a position in CRDL in Q4 2021 and has held it in 12 quarters since. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Citadel Advisors held 819,904 shares of Cardiol Therapeutics worth $1.11M as of Q1 2026.
  • Cardiol Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7440 holding.
  • Citadel Advisors first reported a position in Cardiol Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.